Myelofibrosis is one of the classical Philadelphia chromosome–negative myeloproliferative
neoplasms characterized by progressive marrow failure and chronic inflammation …

Myelofibrosis (MF) is a BCR–ABL1-negative myeloproliferative neoplasm diagnosed de
novo or developed from essential thrombocythemia (ET) or polycythemia vera (PV). Average …

Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for
myelofibrosis (MF) and is recommended for patients with higher risk disease. However …

Myelofibrosis (MF) is a Philadelphia chromosome–negative myeloproliferative neoplasm
associated with bone marrow fibrosis, splenomegaly, a high symptom burden, and poor …

Myelofibrosis (MF) is a clonal stem cell disorder characterized by cytopenias, splenomegaly,
marrow fibrosis, and systemic symptoms due to elevated inflammatory cytokines. MF is …

Introduction: Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by symptoms
mainly derived from anemia and splenomegaly and constitutional symptoms and associated …

Myelofibrosis (MF) is a clonal stem cell neoplasm with heterogeneous clinical phenotypes
and well‐established molecular drivers. Allogeneic haematopoietic stem cell transplantation …

Myelofibrosis (MF) is complex at the pathobiologic level and heterogeneous at the clinical
level. The advances in molecular characterization of MF provide important insight into the …

Despite the curative potential of allogeneic hematopoietic cell transplantation (HCT) for
myelofibrosis (MF), a significant number of patients with MF do not undergo HCT. Factors …

Abstract Purpose of Review To discuss the current treatment paradigm, review novel targets,
and summarize completed and ongoing clinical trials that may lead to a paradigm shifts in …